Hepatocellular carcinoma (HCC) is a common and rapidly progressing malignancy. Current
treatment options for advanced HCC are limited. This clinical study of dendritic cell (DC)-
based immunotherapy for HCC enrolled 31 patients with advanced HCC. DCs, propagated
from peripheral blood monocytes, were pulsed with autologous tumor lysates to treat HCC.
The first 14 patients underwent pulsed therapy with five courses of DC vaccination
intravenously at weekly intervals. The other 17 patients underwent monthly boost …